Population-based trends in prenatal screening and diagnosis for aneuploidy: A retrospective analysis of 38 years of state-wide data

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 123, Issue 1, 2016, Pages 90-97

  Hui, L ^a,b   Muggli, E E ^a,c   Halliday, J L ^a,c  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b MERCY HOSPITAL FOR WOMEN   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Down syndrome; prenatal diagnosis; prenatal screening

Indexed keywords

AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; AUSTRALIAN; CHORION VILLUS SAMPLING; DIAGNOSTIC VALUE; FEMALE; HUMAN; INVASIVE PROCEDURE; MATERNAL SERUM SCREENING TEST; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREND STUDY; TRISOMY 21; ABORTION, SPONTANEOUS; ADULT; ADVERSE EFFECTS; AUSTRALIA; DOWN SYNDROME; GENETIC SCREENING; GESTATIONAL AGE; MATERNAL AGE; METABOLISM; MIDDLE AGED; NEWBORN; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE; PREGNANCY; PROCEDURES; VICTORIA;

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ABORTION, SPONTANEOUS; ADULT; ALPHA-FETOPROTEINS; AMNIOCENTESIS; AUSTRALIA; BIOMARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GENETIC TESTING; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; MATERNAL AGE; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; VICTORIA;

EID: 84952863671     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13488     Document Type: Article

References (32)

1. Halliday JL, Lumley J, Sheffield LJ, Robinson HP, Renou P, Carlin JB,. Importance of complete follow-up of spontaneous fetal loss after amniocentesis and chorion villus sampling. Lancet 1992; 340: 886-90.
2. Mujezinovic F, Alfirevic Z,. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687-94.
3. Tabor A, Alfirevic Z,. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn Ther 2010; 27: 1-7.
4. Nicolaides KH,. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
5. Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH,. Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 2015; 45: 49-66.
6. O'Leary P, Maxwell S, Murch A, Hendrie D,. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 2013; 53: 425-33.
7. Larion S, Warsof SL, Romary L, Mlynarczyk M, Peleg D, Abuhamad AZ,. Association of combined first-trimester screen and noninvasive prenatal testing on diagnostic procedures. Obstet Gynecol 2014; 123: 1303-10.
8. Chetty S, Garabedian MJ, Norton ME,. Uptake of noninvasive prenatal testing (NIPT) in women following positive aneuploidy screening. Prenat Diagn 2013; 33: 542-6.
9. Turner AL, Rad S, Afshar Y, Aghajanian P, Williams J 3rd, Esakoff TF,. Declining rate of invasive procedures for prenatal diagnosis in the era of noninvasive prenatal testing. Obstet Gynecol 2014; 123 (Suppl 1): 196S-7S.
10. Hui L, Bianchi DW,. Recent advances in the prenatal interrogation of the human fetal genome. Trends Genet 2013; 29: 84-91.
11. Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al., Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012; 367: 2175-84.
12. Shaffer LG, Rosenfeld JA, Dabell MP, Coppinger J, Bandholz AM, Ellison JW, et al., Detection rates of clinically significant genomic alterations by microarray analysis for specific anomalies detected by ultrasound. Prenat Diagn 2012; 32: 986-95.
13. American College of Obstetricans and Gynecologists. Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. Obstet Gynecol 2013; 122: 1374-7.
14. Australian Bureau of Statistics. Births, Summary, States and Territories. [ http://www.abs.gov.au/AUSSTATS/absattherate.nsf/DetailsPage/3301.02013?OpenDocument ]. Accessed 23 November 2014.
15. Halliday JL, Muller C,. Prenatal Diagnostic Testing in Victoria 2011. Murdoch Childrens Research Institute. [ https://www.mcri.edu.au/media/296203/pnd-report-2011.pdf ]. Accessed 23 November 2014.
16. Jaques AM, Collins VR, Haynes K, Sheffield LJ, Francis I, Forbes R, et al., Using record linkage and manual follow-up to evaluate the Victorian maternal serum screening quadruple test for Down's syndrome, trisomy 18 and neural tube defects. J Med Screen 2006; 13: 8-13.
17. Jaques AM, Halliday JL, Francis I, Bonacquisto L, Forbes R, Cronin A, et al., Follow up and evaluation of the Victorian first-trimester combined screening programme for Down syndrome and trisomy 18. BJOG 2007; 114: 812-8.
18. Jaques AM, Collins VR, Muggli EE, Amor DJ, Francis I, Sheffield LJ, et al., Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome. Prenat Diagn 2010; 30: 522-30.
19. State Government of Victoria Consultative Council on Obstetric and Paediatric Mortality and Morbidity. 2010 and 2011, Victoria's Mothers and Babies, Victoria's Maternal, Perinatal, Child and Adolescent Mortality 2014. [ http://docs.health.vic.gov.au/docs/doc/Victorias-Mothers-and-Babies-Victorias-Maternal-Perinatal-Child-and-Adolescent-Mortality-2010-2011 ]. Accessed 23 November 2014.
20. Siljee JE, Knegt AC, Knapen MF, Bekker MN, Visser GH, Schielen PC,. Positive predictive values for detection of trisomies 21, 18 and 13 and termination of pregnancy rates after referral for advanced maternal age, first trimester combined test or ultrasound abnormalities in a national screening programme (2007-2009). Prenat Diagn 2014; 34: 259-64.
21. Hui L, Teoh M, da Silva Costa F, Ramsay P, Palma-Dias R, Richmond Z, et al., Clinical implementation of cell-free DNA based aneuploidy screening: perspectives from a national audit. Ultrasound Obstet Gynecol 2015; 45: 10-5.
22. Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH,. Nasal bone in first-trimester screening for trisomy 21. Am J Obstet Gynecol 2006; 195: 109-14.
23. Wapner RJ, Driscoll DA, Simpson JL,. Integration of microarray technology into prenatal diagnosis: counselling issues generated during the NICHD clinical trial. Prenat Diagn 2012; 32: 396-400.
24. Hillman SC, McMullan DJ, Silcock L, Maher ER, Kilby MD,. How does altering the resolution of chromosomal microarray analysis in the prenatal setting affect the rates of pathological and uncertain findings? J Matern Fetal Neonatal Med 2014; 27: 649-57.
25. Riley M,. Population prevalence rates of birth defects: a data management and epidemiological perspective. HIM J 2006; 34: 94-9.
26. Renshaw R, Ellis K, Jacobs P, Morris J,. Antenatal screening for Down syndrome: a quantitative demonstration of the improvements over the past 20 years. J Health Serv Res Policy 2014; 18: 195-201.
27. Comas C, Echevarria M, Rodriguez I, Serra B, Cirigliano V,. Prenatal invasive testing: a 13-year single institution experience. J Matern Fetal Neonatal Med 2014; 27: 1209-12.
28. Collins VR, Muggli EE, Riley M, Palma S, Halliday JL,. Is Down syndrome a disappearing birth defect? J Pediatr 2008; 152: 20-4.
29. Welch RA, Salem-Elgharib S, Wiktor AE, Van Dyke DL, Blessed WB,. Operator experience and sample quality in genetic amniocentesis. Am J Obstet Gynecol 2006; 194: 189-91.
30. Margioula-Siarkou C, Karkanaki A, Kalogiannidis I, Petousis S, Dagklis T, Mavromatidis G, et al., Operator experience reduces the risk of second trimester amniocentesis-related adverse outcomes. Eur J Obstet Gynecol Reprod Biol 2013; 169: 230-3.
31. Chalouhi GE, Bernardi V, Ville Y,. Ultrasound simulators in obstetrics and gynecology: state of the art. Ultrasound Obstet Gynecol 2014; 46: 255-63.
32. Bower CI, Lester-Smith D, Elliott EJ,. Congenital anomalies-why bother? Med J Aust 2010; 192: 300-1.